---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Place in treatment, anticipated use, and care setting. Topics: Summary: place in therapy, Studied use: add-on to standard of care in adults requiring continuous intravenous glucose, Points in the disease course at which medical therapy for hypoglycemia is needed: manufacturer statements, Prior therapies and hospitalization of the expanded access population, and 6 further topics. 10 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: place in therapy

- Ersodetug is investigational and has no approved indication. The FDA orphan drug designation names the treatment of hypoglycemia due to tumor-associated hyperinsulinism, the FDA breakthrough therapy designation names hypoglycemia caused by tumor HI, and the European Union orphan designation (12 January 2024) names insulinoma.
- The studied use is add-on therapy. The phase 3 upLIFT trial enrolls adults 18 years and older with an islet cell or non-islet cell tumor and biochemical evidence of tumor hyperinsulinism who have not achieved adequate control with usual standard-of-care therapies and require IV glucose infusion and/or parenteral nutrition for 7 days or more. Participants receive ersodetug 9 mg/kg weekly for 8 weeks “as an add-on to standard of care”, then may continue in long-term extension at a dosing frequency of every 2 to 4 weeks. Of the 16 enrolled participants, 12 have malignant islet cell tumors (insulinomas) and 4 have non-islet cell tumors.
- In the expanded access publication, all 8 individuals had received and were refractory to at least 3 standard-of-care therapies (diazoxide, somatostatin analogs, everolimus, and/or corticosteroids), and 6 of 8 were hospitalized at entry. Ersodetug was given intravenously over 30 minutes, and the manufacturer states that hospitalized patients were discharged and received maintenance doses as outpatients. Expanded access continues through a registered program (NCT07262970), with drug supplied at no cost under compassionate use programs.
- The manufacturer describes medical therapy as needed from diagnosis to surgery, when surgery is contraindicated or refused, and chronically in patients who cannot be cured by surgery, and names peri-operative management of solitary or benign tumors and solitary or benign tumors where surgery may not be ideal as potential additional settings. It expects to focus its launch on National Cancer Institutes and academic medical centers, where it believes 60% of patients are managed (about 1,000 prescribers and 300 centers), and expects payers to require prior authorization aligned to the label with a step through diazoxide for patients with insulinoma, with reimbursement through a J-code (buy and bill).
- A 2024 clinical review of insulinoma reports successful use of RZ358 in one patient with malignant insulinoma and severe refractory hypoglycemia.

Source: [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723); [Rezolute tumor HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/354/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism); [EMA insulinoma orphan designation (2024)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879); [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism); [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992); [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm); [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.2-2"></a>

### Studied use: add-on to standard of care in adults requiring continuous intravenous glucose

> “Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care.”
> “Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

> “The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).”
> “Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriately elevated insulin or insulin-like growth factor (IGF)/variant suppression) confirmed via laboratory assessment who have failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies, per investigator judgement.”
> “Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administration of the 1st dose of ersodetug).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.2.2.2-3"></a>

### Points in the disease course at which medical therapy for hypoglycemia is needed: manufacturer statements

> “During the period from diagnosis to surgical treatment, or if surgery is contraindicated or refused, medical treatments are often necessary to directly manage the HI and hypoglycemia induced by the tumor.”
> “Additionally, chronic medical management of refractory hypoglycemia is often necessary for patients who cannot be cured by surgery, such as those with extensive disease of the pancreas, multi-focal insulinomas, inoperable or unresectable benign or malignant insulinomas, metastatic insulinomas, non-pancreatic insulinomas or NICT hypoglycemia resulting from a variety of other tumors.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.2.2.2-4"></a>

### Prior therapies and hospitalization of the expanded access population

> “All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.”
> “Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “All patients received ersodetug in open-label fashion at doses of 6 or 9 mg/kg every 1-2 weeks initially, followed by a frequency of every 2-4 weeks as tolerated, as add on to standard of care (e.g. diazoxide, somatostatin analogues, etc.), which could be weaned as appropriate”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-2.2.2.2-5"></a>

### Care setting: inpatient initiation and outpatient maintenance infusions

> “Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “hospitalized patients were able to be discharged and receive maintenance ersodetug doses on an outpatient basis, with durable benefit.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.2.2.2-6"></a>

### Launch focus and concentration of treating centers

> “We believe 60% of these patients are managed at the National Cancer Institutes and academic medical centers, which will be our primary focus at launch.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “~1,000 HCPs treat 60% of patients”
> “300 centers manage 60% of patients”
> “High penetration with a small number of treaters at National Cancer Institutes and Academic Medical Centers”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.2-7"></a>

### Anticipated payer management and reimbursement pathway

> “Expect to manage ersodetug with a prior authorization aligned to the label and a step-through diazoxide for patients with insulinoma”
> “Inclusion in NCCN and ENDO Society guidelines expedites the payer approval process”
> “Expect institutions, particularly NCI-designated centers, to be adept at navigating the medical exception process for payer approvals”
> “Reimbursement via J-code (buy and bill) simplifies the approval administration burden”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.2-8"></a>

### Potential additional settings named by the manufacturer

> “Peri-operative management of solitary / benign tumors”
> “Solitary/benign tumors where surgery may not be ideal (e.g., contraindications or inability to localize)”
> “Inclusion in the NCCN guidelines helps patient identification and payer reimbursement”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.2-9"></a>

### Mention of ersodetug in a clinical practice review of insulinoma

> “Recently, the successful use of RZ358 was reported in a patient with severe refractory hypoglycemia and a malignant insulinoma”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.2-10"></a>

### Guideline framework for advanced functioning pancreatic neuroendocrine tumors

> “Management of each functioning Pan-NET syndrome in patients with advanced disease requires a tailored multimodal approach of supportive, surgical, interventional, hormonal and antiproliferative therapies [5, A].”
> “When dedicated supportive therapy for a functioning Pan-NET syndrome is insufficient, palliative SSA treatment can be initiated.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

Additional sources: [NCCN Neuroendocrine and Adrenal Tumors guideline](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
